Clinical Ink Blog Navigating Patient-Reported Outcome (PRO) Data in Cancer Clinical Trials: Insights from the FDA's Latest Guidance

The recent FDA publication "Submitting Patient-Reported Outcome (PRO) Data in Cancer Clinical Trials'' represents a significant leap forward in cancer research and drug development. This detailed guidance for integrating PROs into the drug approval process sets a new standard for the evaluation of cancer treatments.The post Navigating Patient-Reported Outcome (PRO) Data in Cancer Clinical Trials: Insights from the FDA's Latest Guidance appeared first on Clinical ink.